These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27350724)

  • 1. Natural regression of fibrosis in chronic hepatitis B.
    Ohkoshi S; Hirono H; Watanabe K; Hasegawa K; Kamimura K; Yano M
    World J Gastroenterol; 2016 Jun; 22(24):5459-66. PubMed ID: 27350724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
    Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What can we learn from hepatitis B virus clinical cohorts?
    Lin CL; Tseng TC; Kao JH
    Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
    Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
    J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B.
    Lin CL; Kao JH
    J Biomed Sci; 2008 Mar; 15(2):137-45. PubMed ID: 18058038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.
    Xu B; Lin L; Xu G; Zhuang Y; Guo Q; Liu Y; Wang H; Zhou X; Wu S; Bao S; Cai W; Xie Q
    J Gastroenterol Hepatol; 2015 Feb; 30(2):372-8. PubMed ID: 25167956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.
    Hsu YS; Chien RN; Yeh CT; Sheen IS; Chiou HY; Chu CM; Liaw YF
    Hepatology; 2002 Jun; 35(6):1522-7. PubMed ID: 12029639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
    Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
    J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
    Zhou TC; Lai X; Feng MH; Tang Y; Zhang L; Wei J
    J Viral Hepat; 2018 Oct; 25(10):1172-1179. PubMed ID: 29741285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval.
    Mak LY; Seto WK; Hui RW; Fung J; Wong DK; Lai CL; Yuen MF
    J Viral Hepat; 2019 Jul; 26(7):818-827. PubMed ID: 30895682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.
    Fattovich G; Bortolotti F; Donato F
    J Hepatol; 2008 Feb; 48(2):335-52. PubMed ID: 18096267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B: liver fibrosis and hepatocellular carcinoma.
    Lok AS
    Gastroenterol Clin Biol; 2009; 33(10-11):911-5. PubMed ID: 19577871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common clinicopathological features of the patients with chronic hepatitis B virus infection who developed hepatocellular carcinoma after seroconversion to anti-HBs--a consideration of the pathogenesis of HBV-induced hepatocellular carcinoma and a strategy to inhibit it.
    Tsuboi Y; Ohkoshi S; Yano M; Suzuki K; Tsubata SS; Ishihara K; Ichida T; Sugitani S; Shibazaki K; Aoyagi Y
    Hepatogastroenterology; 2006; 53(67):110-4. PubMed ID: 16506387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
    Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
    J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
    Poynard T; Vergniol J; Ngo Y; Foucher J; Thibault V; Munteanu M; Merrouche W; Lebray P; Rudler M; Deckmyn O; Perazzo H; Thabut D; Ratziu V; de Ledinghen V;
    J Hepatol; 2014 Nov; 61(5):994-1003. PubMed ID: 25016224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients.
    Chen CH; Hung CH; Lee CM; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
    Gastroenterology; 2007 Nov; 133(5):1466-74. PubMed ID: 17915220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of hepatitis B.
    Marcellin P; Castelnau C; Martinot-Peignoux M; Boyer N
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):63-75. PubMed ID: 15756147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?
    Kara B; Doran F; Kara IO; Akkiz H; Sandikci M
    Int J Clin Pract; 2008 Aug; 62(8):1206-11. PubMed ID: 18284441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
    Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
    Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.